Aytu BioPharma Inc (LTS:0A8M)

$ 1.59 -0.01 (-0.62%) Market Cap: 9.90 Mil Enterprise Value: 6.35 Mil PE Ratio: 0 PB Ratio: 0.33 GF Score: 40/100

Q1 2025 Aytu Biopharma Inc Earnings Call Transcript
Nov 13, 2024

$1.77 (-1.67%)

Earnings
Q4 2024 Aytu Biopharma Inc Earnings Call Transcript
Sep 26, 2024

$2.5 (+0.40%)

Earnings
Q3 2024 Aytu Biopharma Inc Earnings Call Transcript
May 15, 2024

$3.37 (-0.88%)

Earnings
Q2 2024 Aytu Biopharma Inc Earnings Call Transcript
Feb 14, 2024

$3.21 (+11.28%)

Earnings
Q1 2024 Aytu Biopharma Inc Earnings Call Transcript
Nov 14, 2023

$2.67 (+1.52%)

Earnings
Aytu Biopharma Inc at Lytham Partners Fall Investor Conference Transcript
Oct 17, 2023
Q4 2023 Aytu Biopharma Inc Earnings Call Transcript
Sep 27, 2023

$1.79 (+14.30%)

Earnings
Q3 2023 Aytu Biopharma Inc Earnings Call Transcript
May 11, 2023

$2.17 (+6.90%)

Earnings
Q2 2023 Aytu Biopharma Inc Earnings Call Transcript
Feb 21, 2023

$4.06

Earnings
Q1 2023 Aytu Biopharma Inc Earnings Call Transcript
Nov 14, 2022

$4.09 (+15.32%)

Earnings
Q4 2022 Aytu Biopharma Inc Earnings Call Transcript
Sep 27, 2022

$3.8 (-0.05%)

Earnings
Q1 2022 Aytu Biopharma Inc Earnings Call Transcript
Nov 15, 2021

$50.57 (+1.75%)

Earnings
Q4 2021 Aytu Biopharma Inc Earnings Call Transcript
Sep 27, 2021

$64.2 (+8.81%)

Earnings
Aytu Biopharma Inc Annual Shareholders Meeting Transcript
May 21, 2021
Q3 2021 Aytu Biopharma Inc Earnings Call Transcript
May 17, 2021

$109.8 (+1.48%)

Earnings
Aytu Biopharma Inc to Discuss the Rumpus Transaction and the AR101 Scientific Background- Conference Call Transcript
Apr 12, 2021
Aytu BioScience Inc Extraordinary Shareholders Meeting Transcript
Mar 18, 2021
Q2 2021 Aytu BioScience Inc Earnings Call Transcript
Feb 11, 2021

Earnings
Aytu BioScience Inc at LD Micro Main Event Transcript
Dec 15, 2020
Aytu BioScience Inc to Acquire Neos Therapeutics Inc- M&A Call Transcript
Dec 10, 2020
Q1 2021 Aytu BioScience Inc Earnings Call Transcript
Nov 12, 2020

Earnings
Q4 2020 Aytu BioScience Inc Earnings Call Transcript
Oct 06, 2020

Earnings
Q3 2020 Aytu BioScience Inc Earnings Call Transcript
May 14, 2020

Earnings
Aytu BioScience Inc COVID-19 Initiatives Update Call Transcript
Apr 21, 2020
Q2 2020 Aytu BioScience Inc Earnings Call Transcript
Feb 13, 2020

Earnings
Q1 2020 Aytu BioScience Inc Earnings Call Transcript
Nov 14, 2019

Earnings
Aytu BioScience Inc Acquires Prescription Product Portfolio from Cerecor Inc - M&A Call Transcript
Oct 14, 2019
Q4 2019 Aytu BioScience Inc Earnings Call Transcript
Sep 26, 2019

Earnings
Q3 2019 Aytu BioScience Inc Earnings Call Transcript
May 14, 2019

Earnings

Q2 2023 Aytu Biopharma Inc Earnings Call Transcript

Feb 21, 2023 / 09:30PM GMT

Release Date Price: $4.06

Transcript 10-Q10-Q/A8-K

Operator

Greetings. Welcome to Aytu Biopharma fiscal 2023 Q2 results conference call. (Operator Instructions) Please note this conference is being recorded.

I will now turn the conference over to your host, Roger Weiss. You may begin.

Roger Weiss

Lytham Partners - IR

Good afternoon, everyone, and thank you for joining us for Aytu BioPharma's second quarter fiscal year 2023 financial results conference call. Joining us today on the call is Aytu's CEO, Josh Disbrow; and the company's Chief Financial Officer, Mark Oki.

At the conclusion of today's prepared remarks, we'll open the call for a question-and-answer session. I'd like to remind everyone that today's call is being recorded. A replay of today's call will be available by using the telephone numbers and conference ID provided in the earnings press release issued earlier today.

Finally, I'd also like to call your attention to the customary Safe Harbor disclosure regarding forward-looking information. The conference call today will contain certain forward-looking statements, including

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.